As part of the partnership, PPC will use the Patient Network Explorer platform to advance clinical trials, trial enrollment, and accelerate global studies conducted in the People’s Republic of China, the Republic of China (Taiwan) and the Republic of Korea (South Korea). PPC will encourage hospitals to participate in Clinerion’s Patient Network Explorer platform for generation of RWD/RWE and bringing more global studies to hospitals.
PPC provides a fully integrated solution for Phase I-IV studies in Asian countries. PPC is dedicated to serve the pharmaceutical and biotechnology industry with world-class quality and cost-effective solutions to shorten the lead time to market. PPC provides full services for clinical trials, such as Project Management, Regulatory Affairs, Clinical Monitoring, Biostatistics, Data Management, Medical Writing, and Pharmacovigilance.
Patient Network Explorer supports patient health by matching patients from Clinerion’s global network of hospitals to clinical trials conducted by pharmaceutical sponsors or researchers performing academic investigations. The system is based on de-identified EHR data, unlinked from any identifiers, protecting patient privacy. The partners’ combined services will accelerate access for patients and hospitals to next-generation medical treatments. Patients in the region will become more visible to sponsors for trial recruitment, and hospitals in the region will become better placed to run clinical trials, ultimately accelerating drug launch.
“We are excited to be partnering with Clinerion to jointly offer our customers access to global integrated recruitment services through the Patient Network Explorer platform,” says Michael Stibilj, CEO of PPC. “This relationship will enable researchers and hospitals, in our region, to have additional opportunities to be involved in global trials, also providing patients access to new potential treatments. Increased access to patients will speed up the clinical trial process and help accelerate the development of break-through products.”
“The strength of Patient Network Explorer lies in its global coverage,” says Ian Rentsch, Clinerion CEO. “Clinerion’s hospital network currently covers 19 countries and over 73 M patients. The partnership with PPC promises to deepen our presence in Korea and Taiwan, and expand our coverage to China. Clinerion continues to build our global presence!”
About Clinerion
Clinerion accelerates clinical research and medical access to treatments for patients. We use proprietary technologies for analysis of patient data from our global network of partner hospitals. Clinerion’s Patient Network Explorer radically improves the efficiency and effectiveness of clinical trial recruitment by offering data-driven protocol optimization, site feasibility evaluation and real-time patient search and identification to match patients to treatments. Our technology solution provides real-world evidence analytics for medical access. Clinerion facilitates the participation of partner hospitals in leading-edge, industry-sponsored trials and time savings in patient recruitment. We create innovative and disruptive fit-for-purpose solutions which enable pharmaceutical companies to shorten patient recruitment and save costs by streamlining operations and leveraging strategic intelligence. Clinerion’s proprietary Big Data analytics technologies leverage real-time data from electronic health records which comply with international patient privacy and data security regulations. Clinerion is a global data technology service company headquartered in Switzerland.
Clinerion website: www.clinerion.com
Clinerion’s Patient Network Explorer: www.clinerion.com/index/OverviewOurSolutions/ClinerionPatientNetworkExplorer
For more information, please contact:
Le Vin Chin
Director, Head of Marketing & Communications
Clinerion Ltd
Elisabethenanlage 11, 4051 Basel, Switzerland
Tel.: +41 61 865 60 54
About PPC.
PPC group was founded in 1997, provides professional services for clinical studies to pharmaceutical and biotechnology companies. PPC offers clinical and laboratory services in China, Taiwan, Korea and Japan. Since 1997, PPC has completed over 2000 early phase trials including innovative phase I pharmacokinetic, generic bioequivalence and biosimilar studies for local and global pharmaceuticals companies in Asia. In addition, PPC has conducted over 500 innovative phase II- IV trials, covering 24 therapeutic areas. PPC group has 7 offices, 4 phase I units, 3 bioanalytical labs and 1 central lab in China, Taiwan, Korea and Japan, employing over 600 staff.
PPC website: www.ppccro.com
For more information, please contact:
Gerard Kim
Business Development Associate
PPC Korea Co., Ltd.
20F, SamWon Tower 124, Teheran-ro, Gangnam-gu, Seoul, Korea, 06234
Tel.: +82 2 2054 0651
Fax: +82 2 535 0511
Mobile: +82 10 5264 4105
